Le Lézard
Classified in: Health, Business
Subjects: ERP, ACC, MAT

Update on Saskatchewan Crop and Transaction With BioHemp Naturals


VANCOUVER, British Columbia, Aug. 15, 2019 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM.CN) (MYM.CN) (OTCBB: MYMMF) ("MYM Nutraceuticals" or the "Company") announces it has determined that the amount of biomass anticipated to be cultivated by BioHemp Naturals Growing & Farming Ltd. ("Bio Hemp") on its Saskatchewan farms will be significantly less than original estimates.

We are currently assessing various options to rescind the transaction, the anticipated effect of which would be that it never occurred.  MYM expects to report shortly on the outcome of this process.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and CBD-rich hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the United States under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Howard Steinberg, CEO
MYM Nutraceuticals Inc.
www.mym.ca

Investor Relations
Billy Casselman
778-522-2261
investors@mym.ca

Keep up to date with MYM on our social media channels:

Twitter: @mymnutra
Facebook: @mymnutra
Instagram: @mymnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. The Company disclaims and does not undertake any intention or obligation to revise or update such statements, except as required by applicable law. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis dated April 24, 2019 (the "MD&A") and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Forward-looking statements may include, without limitation, statements relating to, but not limited to, the Company's ability to rescind the acquisition of its 50% interest in Bio Hemp on acceptable terms..

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Billy Casselman
778-522-2261
investors@mym.ca

 

 

 

SOURCE MYM Nutraceuticals Inc.


These press releases may also interest you

at 02:40
The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced...

at 02:35
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed the expansion of the rights available to it from Cambridge Enterprise, enabling the...

at 02:05
Agilent Technologies Inc. announced today that Professor Hualiang Jiang has received an Agilent Thought Leader Award. Professor Jiang directs the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences and is a leading researcher in...

at 01:05
Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with BioLizard, an innovative bioinformatics company that...

at 01:05
Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was...

at 00:05
Last year, over 23,500 youth (age 10 to 24) were hospitalizedi for harm caused by substance use ? the equivalent of 65 hospitalizations each day. A new report from the Canadian Institute for Health Information (CIHI) shows that cannabis and alcohol...



News published on 15 august 2019 at 08:30 and distributed by: